{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:35:05Z","timestamp":1790739305525,"version":"4.1.0"},"publisher-location":"Cham","reference-count":150,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030220044","type":"print"},{"value":"9783030220051","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/164_2019_232","type":"book-chapter","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T05:49:04Z","timestamp":1560404944000},"page":"167-205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Nonsteroidal FXR Ligands: Current Status and Clinical Applications"],"prefix":"10.1007","author":[{"given":"Christian","family":"Gege","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hambruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Hambruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Kinzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Kremoser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,14]]},"reference":[{"issue":"4","key":"232_CR1","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1172\/JCI64551","volume":"123","author":"F Alemi","year":"2013","unstructured":"Alemi F, Kwon E, Poole DP, Lieu T, Lyo V, Cattaruzza F et al (2013) The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest 123(4):1513\u20131530","journal-title":"J Clin Invest"},{"issue":"6","key":"232_CR2","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1073\/pnas.72.6.2423","volume":"72","author":"BN Ames","year":"1975","unstructured":"Ames BN, Kammen HO, Yamasaki E (1975) Hair dyes are mutagenic: identification of a variety of mutagenic ingredients. Proc Natl Acad Sci U S A 72(6):2423\u20132427","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"232_CR3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/cmdc.200900499","volume":"5","author":"S Amslinger","year":"2010","unstructured":"Amslinger S (2010) The tunable functionality of alpha,beta-unsaturated carbonyl compounds enables their differential application in biological systems. ChemMedChem 5(3):351\u2013356","journal-title":"ChemMedChem"},{"issue":"31","key":"232_CR4","doi-asserted-by":"publisher","first-page":"28857","DOI":"10.1074\/jbc.M011610200","volume":"276","author":"M Ananthanarayanan","year":"2001","unstructured":"Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ (2001) Human bile salt export pump promoter is transactivated by the farnesoid X receptor\/bile acid receptor. J Biol Chem 276(31):28857\u201328865","journal-title":"J Biol Chem"},{"key":"232_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/1756-0500-5-461","volume":"5","author":"R Attinkara","year":"2012","unstructured":"Attinkara R, Mwinyi J, Truninger K, Regula J, Gaj P, Rogler G et al (2012) Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease. BMC Res Notes 5:461","journal-title":"BMC Res Notes"},{"issue":"1","key":"232_CR6","doi-asserted-by":"publisher","first-page":"G48","DOI":"10.1152\/ajpgi.00234.2013","volume":"306","author":"AM Bailey","year":"2014","unstructured":"Bailey AM, Zhan L, Maru D, Shureiqi I, Pickering CR, Kiriakova G et al (2014) FXR silencing in human colon cancer by DNA methylation and KRAS signaling. Am J Physiol Gastrointest Liver Physiol 306(1):G48\u2013G58","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"Suppl 1","key":"232_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/liv.13301","volume":"37","author":"P Bedossa","year":"2017","unstructured":"Bedossa P (2017) Pathology of non-alcoholic fatty liver disease. Liver Int 37(Suppl 1):85\u201389","journal-title":"Liver Int"},{"issue":"1","key":"232_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.mrrev.2004.08.001","volume":"589","author":"H Bernstein","year":"2005","unstructured":"Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H (2005) Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res 589(1):47\u201365","journal-title":"Mutat Res"},{"issue":"Suppl 1","key":"232_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-017-9827-9","volume":"12","author":"J Bosch","year":"2018","unstructured":"Bosch J, Iwakiri Y (2018) The portal hypertension syndrome: etiology, classification, relevance, and animal models. Hepatol Int 12(Suppl 1):1\u201310","journal-title":"Hepatol Int"},{"issue":"6","key":"232_CR10","doi-asserted-by":"publisher","first-page":"G1124","DOI":"10.1152\/ajpgi.00539.2005","volume":"290","author":"JL Boyer","year":"2006","unstructured":"Boyer JL, Trauner M, Mennone A, Soroka CJ, Cai S-Y, Moustafa T et al (2006) Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol 290(6):G1124\u2013G1130","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"6652","key":"232_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/39645","volume":"389","author":"AM Brzozowski","year":"1997","unstructured":"Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstr\u00f6m O et al (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389(6652):753\u2013758","journal-title":"Nature"},{"issue":"3","key":"232_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1021\/bi101762x","volume":"50","author":"YA Bulynko","year":"2011","unstructured":"Bulynko YA, O\u2019Malley BW (2011) Nuclear receptor coactivators: structural and functional biochemistry. Biochemistry (Mosc) 50(3):313\u2013328","journal-title":"Biochemistry (Mosc)"},{"issue":"2","key":"232_CR13","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1124\/pr.112.006833","volume":"65","author":"TP Burris","year":"2013","unstructured":"Burris TP, Solt LA, Wang Y, Crumbley C, Banerjee S, Griffett K et al (2013) Nuclear receptors and their selective pharmacologic modulators. Pharmacol Rev 65(2):710\u2013778","journal-title":"Pharmacol Rev"},{"issue":"1 Suppl","key":"232_CR14","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G (2015) NAFLD: a multisystem disease. J Hepatol 62(1 Suppl):S47\u2013S64","journal-title":"J Hepatol"},{"issue":"1","key":"232_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11549-7","volume":"7","author":"M Cariello","year":"2017","unstructured":"Cariello M, Peres C, Zerlotin R, Porru E, Sabb\u00e0 C, Roda A et al (2017) Long-term administration of nuclear bile acid receptor FXR agonist prevents spontaneous hepatocarcinogenesis in Abcb4\u2212\/\u2212 mice. Sci Rep 7(1):11203","journal-title":"Sci Rep"},{"issue":"16","key":"232_CR16","doi-asserted-by":"publisher","first-page":"11039","DOI":"10.1074\/jbc.M510258200","volume":"281","author":"B Cariou","year":"2006","unstructured":"Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M et al (2006) The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 281(16):11039\u201311049","journal-title":"J Biol Chem"},{"issue":"7","key":"232_CR17","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","volume":"152","author":"O Ch\u00e1vez-Talavera","year":"2017","unstructured":"Ch\u00e1vez-Talavera O, Tailleux A, Lefebvre P, Staels B (2017) Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology 152(7):1679\u20131694.e3","journal-title":"Gastroenterology"},{"issue":"2","key":"232_CR18","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1053\/j.gastro.2009.06.027","volume":"137","author":"N Chignard","year":"2009","unstructured":"Chignard N, Poupon R (2009) Targeting farnesoid x receptor in hepatic and biliary inflammatory diseases. Gastroenterology 137(2):734\u2013735; discussion 736","journal-title":"Gastroenterology"},{"issue":"4","key":"232_CR19","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1194\/jlr.M001602","volume":"51","author":"S Cipriani","year":"2010","unstructured":"Cipriani S, Mencarelli A, Palladino G, Fiorucci S (2010) FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa\/fa) obese rats. J Lipid Res 51(4):771\u2013784","journal-title":"J Lipid Res"},{"issue":"3","key":"232_CR20","first-page":"259","volume":"14","author":"I Copaci","year":"2005","unstructured":"Copaci I, Micu L, Iliescu L, Voiculescu M (2005) New therapeutical indications of ursodeoxycholic acid. Rom J Gastroenterol 14(3):259\u2013266","journal-title":"Rom J Gastroenterol"},{"issue":"3","key":"232_CR21","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"Corpechot C, Abenavoli L, Rabahi N, Chr\u00e9tien Y, Andr\u00e9ani T, Johanet C et al (2008) Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 48(3):871\u2013877","journal-title":"Hepatology"},{"issue":"5","key":"232_CR22","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1053\/j.gastro.2016.12.037","volume":"152","author":"JF de Boer","year":"2017","unstructured":"de Boer JF, Schonewille M, Boesjes M, Wolters H, Bloks VW, Bos T et al (2017) Intestinal farnesoid X receptor controls transintestinal cholesterol excretion in mice. Gastroenterology 152(5):1126\u20131138.e6","journal-title":"Gastroenterology"},{"issue":"6","key":"232_CR23","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1023\/B:DDAS.0000034558.78747.98","volume":"49","author":"A de Gottardi","year":"2004","unstructured":"de Gottardi A, Touri F, Maurer CA, Perez A, Maurhofer O, Ventre G et al (2004) The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig Dis Sci 49(6):982\u2013989","journal-title":"Dig Dis Sci"},{"key":"232_CR24","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0027-5107(01)00195-6","volume":"480\u2013481","author":"PR Debruyne","year":"2001","unstructured":"Debruyne PR, Bruyneel EA, Li X, Zimber A, Gespach C, Mareel MM (2001) The role of bile acids in carcinogenesis. Mutat Res 480\u2013481:359\u2013369","journal-title":"Mutat Res"},{"issue":"10","key":"232_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043044","volume":"7","author":"U Deuschle","year":"2012","unstructured":"Deuschle U, Sch\u00fcler J, Schulz A, Schl\u00fcter T, Kinzel O, Abel U et al (2012) FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model. PLoS One 7(10):e43044","journal-title":"PLoS One"},{"issue":"2","key":"232_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.apsb.2015.01.004","volume":"5","author":"L Ding","year":"2015","unstructured":"Ding L, Yang L, Wang Z, Huang W (2015) Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin B 5(2):135\u2013144","journal-title":"Acta Pharm Sin B"},{"issue":"4","key":"232_CR27","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S1097-2765(03)00104-7","volume":"11","author":"M Downes","year":"2003","unstructured":"Downes M, Verdecia MA, Roecker AJ, Hughes R, Hogenesch JB, Kast-Woelbern HR et al (2003) A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell 11(4):1079\u20131092","journal-title":"Mol Cell"},{"issue":"5","key":"232_CR28","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z et al (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65(5):1557\u20131565","journal-title":"Hepatology"},{"issue":"6","key":"232_CR29","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1210\/me.2010-0512","volume":"25","author":"SKD Dwivedi","year":"2011","unstructured":"Dwivedi SKD, Singh N, Kumari R, Mishra JS, Tripathi S, Banerjee P et al (2011) Bile acid receptor agonist GW4064 regulates PPAR\u03b3 coactivator-1\u03b1 expression through estrogen receptor-related receptor \u03b1. Mol Endocrinol 25(6):922\u2013932","journal-title":"Mol Endocrinol"},{"issue":"3","key":"232_CR30","doi-asserted-by":"publisher","first-page":"G543","DOI":"10.1152\/ajpgi.90585.2008","volume":"296","author":"MJ Evans","year":"2009","unstructured":"Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA et al (2009) A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol 296(3):G543\u2013G552","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"232_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nm.3760","volume":"21","author":"S Fang","year":"2015","unstructured":"Fang S, Suh JM, Reilly SM, Yu E, Osborn O, Lackey D et al (2015) Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 21(2):159\u2013165","journal-title":"Nat Med"},{"issue":"6","key":"232_CR32","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.2353\/ajpath.2009.090114","volume":"175","author":"P Fickert","year":"2009","unstructured":"Fickert P, Fuchsbichler A, Moustafa T, Wagner M, Zollner G, Halilbasic E et al (2009) Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol 175(6):2392\u20132405","journal-title":"Am J Pathol"},{"issue":"7","key":"232_CR33","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/hep4.1079","volume":"1","author":"C Filozof","year":"2017","unstructured":"Filozof C, Chow S-C, Dimick-Santos L, Chen Y-F, Williams RN, Goldstein BJ et al (2017) Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: facilitating development approaches for an emerging epidemic. Hepatol Commun 1(7):577\u2013585","journal-title":"Hepatol Commun"},{"issue":"5","key":"232_CR34","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","volume":"127","author":"S Fiorucci","year":"2004","unstructured":"Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L et al (2004) The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127(5):1497\u20131512","journal-title":"Gastroenterology"},{"issue":"2","key":"232_CR35","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1124\/jpet.104.079665","volume":"313","author":"S Fiorucci","year":"2005","unstructured":"Fiorucci S, Clerici C, Antonelli E, Orlandi S, Goodwin B, Sadeghpour BM et al (2005a) Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther 313(2):604\u2013612","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"232_CR36","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1124\/jpet.105.084905","volume":"314","author":"S Fiorucci","year":"2005","unstructured":"Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L et al (2005b) A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther 314(2):584\u2013595","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"232_CR37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1124\/jpet.105.085597","volume":"315","author":"S Fiorucci","year":"2005","unstructured":"Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L et al (2005c) Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther 315(1):58\u201368","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"232_CR38","first-page":"1449","volume":"18","author":"S Fiorucci","year":"2014","unstructured":"Fiorucci S, Distrutti E, Ricci P, Giuliano V, Donini A, Baldelli F (2014) Targeting FXR in cholestasis: hype or hope. Expert Opin Ther Targets 18(12):1449\u20131459","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"232_CR39","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1021\/jm8014124","volume":"52","author":"B Flatt","year":"2009","unstructured":"Flatt B, Martin R, Wang T-L, Mahaney P, Murphy B, Gu X-H et al (2009) Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem 52(4):904\u2013907","journal-title":"J Med Chem"},{"issue":"5","key":"232_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036713","volume":"7","author":"DM French","year":"2012","unstructured":"French DM, Lin BC, Wang M, Adams C, Shek T, H\u00f6tzel K et al (2012) Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One 7(5):e36713","journal-title":"PLoS One"},{"issue":"7","key":"232_CR41","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.bbalip.2010.04.006","volume":"1801","author":"RM Gadaleta","year":"2010","unstructured":"Gadaleta RM, van Mil SWC, Oldenburg B, Siersema PD, Klomp LWJ, van Erpecum KJ (2010) Bile acids and their nuclear receptor FXR: relevance for hepatobiliary and gastrointestinal disease. Biochim Biophys Acta 1801(7):683\u2013692","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"232_CR42","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/gut.2010.212159","volume":"60","author":"RM Gadaleta","year":"2011","unstructured":"Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen ECL, Renooij W, Murzilli S et al (2011) Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60(4):463\u2013472","journal-title":"Gut"},{"issue":"5","key":"232_CR43","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1194\/jlr.M033423","volume":"54","author":"C Gard\u00e8s","year":"2013","unstructured":"Gard\u00e8s C, Chaput E, Staempfli A, Blum D, Richter H, Benson GM (2013) Differential regulation of bile acid and cholesterol metabolism by the farnesoid X receptor in Ldlr \u2212\/\u2212 mice versus hamsters. J Lipid Res 54(5):1283\u20131299","journal-title":"J Lipid Res"},{"issue":"19","key":"232_CR44","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.2174\/1568026614666141112094430","volume":"14","author":"C Gege","year":"2014","unstructured":"Gege C, Kinzel O, Steeneck C, Schulz A, Kremoser C (2014) Knocking on FXR\u2019s door: the \u2018hammerhead\u2019-structure series of FXR agonists \u2013 amphiphilic isoxazoles with potent in vitro and in vivo activities. Curr Top Med Chem 14(19):2143\u20132158","journal-title":"Curr Top Med Chem"},{"issue":"24","key":"232_CR1000","doi-asserted-by":"publisher","first-page":"9768","DOI":"10.1021\/acs.jmedchem.5b01161","volume":"58","author":"MJ Genin","year":"2015","unstructured":"Genin MJ, Bueno AB, Agejas Francisco J, Manninen PR, Bocchinfuso WP, Montrose-Rafizadeh C et al (2015) Discovery of 6-(4-{[5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic acid: a novel FXR agonist for the treatment of dyslipidemia. J Med Chem 58(24):9768\u20139772","journal-title":"J Med Chem"},{"issue":"1","key":"232_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/108705710200700102","volume":"7","author":"JF Glickman","year":"2002","unstructured":"Glickman JF, Wu X, Mercuri R, Illy C, Bowen BR, He Y et al (2002) A comparison of ALPHAScreen, TR-FRET, and TRF as assay methods for FXR nuclear receptors. J Biomol Screen 7(1):3\u201310","journal-title":"J Biomol Screen"},{"issue":"9","key":"232_CR46","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1111\/liv.13880","volume":"38","author":"J Goldstein","year":"2018","unstructured":"Goldstein J, Levy C (2018) Novel and emerging therapies for cholestatic liver diseases. Liver Int 38(9):1520\u20131535","journal-title":"Liver Int"},{"issue":"3","key":"232_CR47","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","volume":"6","author":"B Goodwin","year":"2000","unstructured":"Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB et al (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6(3):517\u2013526","journal-title":"Mol Cell"},{"issue":"11","key":"232_CR48","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/nrd1551","volume":"3","author":"H Gronemeyer","year":"2004","unstructured":"Gronemeyer H, Gustafsson J-A, Laudet V (2004) Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3(11):950\u2013964","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"232_CR49","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","volume":"67","author":"H Hagstr\u00f6m","year":"2017","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, Hammar U, St\u00e5l P, Hultcrantz R et al (2017) Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 67(6):1265\u20131273","journal-title":"J Hepatol"},{"issue":"3","key":"232_CR50","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1124\/jpet.112.196519","volume":"343","author":"E Hambruch","year":"2012","unstructured":"Hambruch E, Miyazaki-Anzai S, Hahn U, Matysik S, Boettcher A, Perovi\u0107-Ottstadt S et al (2012) Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (\u2212\/\u2212) mice. J Pharmacol Exp Ther 343(3):556\u2013567","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"232_CR51","first-page":"756","volume":"12","author":"WN Hannah","year":"2016","unstructured":"Hannah WN, Torres DM, Harrison SA (2016) Nonalcoholic steatohepatitis and endpoints in clinical trials. Gastroenterol Hepatol 12(12):756\u2013763","journal-title":"Gastroenterol Hepatol"},{"issue":"6","key":"232_CR52","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1194\/jlr.M800619-JLR200","volume":"50","author":"HB Hartman","year":"2009","unstructured":"Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA, Evans MJ (2009) Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR\u2212\/\u2212 and apoE\u2212\/\u2212 mice. J Lipid Res 50(6):1090\u20131100","journal-title":"J Lipid Res"},{"issue":"1","key":"232_CR53","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jhep.2008.08.015","volume":"50","author":"HK Ho","year":"2009","unstructured":"Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS et al (2009) Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 50(1):118\u2013127","journal-title":"J Hepatol"},{"issue":"13","key":"232_CR54","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1101\/gad.1083503","volume":"17","author":"JA Holt","year":"2003","unstructured":"Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF et al (2003) Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 17(13):1581\u20131591","journal-title":"Genes Dev"},{"issue":"6","key":"232_CR55","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1210\/me.2007-0113","volume":"21","author":"SM Houten","year":"2007","unstructured":"Houten SM, Volle DH, Cummins CL, Mangelsdorf DJ, Auwerx J (2007) In vivo imaging of farnesoid X receptor activity reveals the ileum as the primary bile acid signaling tissue. Mol Endocrinol 21(6):1312\u20131323","journal-title":"Mol Endocrinol"},{"key":"232_CR56","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.biochi.2017.10.019","volume":"143","author":"M Hu","year":"2017","unstructured":"Hu M, Phan F, Bourron O, Ferr\u00e9 P, Foufelle F (2017) Steatosis and NASH in type 2 diabetes. Biochimie 143:37\u201341","journal-title":"Biochimie"},{"issue":"1","key":"232_CR57","doi-asserted-by":"publisher","first-page":"S425","DOI":"10.1016\/S0168-8278(17)31214-X","volume":"66","author":"K Huttner","year":"2017","unstructured":"Huttner K, Desai S, DeCristofaro M, Laffitte B, Lin T, Chen J et al (2017) First-in-human study of LMB763, a novel, orally-available farnesoid X receptor agonist that demonstrates modulation of the pharmacodynamic markers FGF19 and C4 in healthy subjects. J Hepatol 66(1):S425","journal-title":"J Hepatol"},{"issue":"4","key":"232_CR58","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","volume":"2","author":"T Inagaki","year":"2005","unstructured":"Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG et al (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2(4):217\u2013225","journal-title":"Cell Metab"},{"issue":"3","key":"232_CR59","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/hep.26146","volume":"57","author":"Y Jiang","year":"2013","unstructured":"Jiang Y, Iakova P, Jin J, Sullivan E, Sharin V, Hong I-H et al (2013) Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer. Hepatology 57(3):1098\u20131106","journal-title":"Hepatology"},{"key":"232_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10166","volume":"6","author":"C Jiang","year":"2015","unstructured":"Jiang C, Xie C, Lv Y, Li J, Krausz KW, Shi J et al (2015) Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun 6:10166","journal-title":"Nat Commun"},{"issue":"1","key":"232_CR61","doi-asserted-by":"publisher","first-page":"S690","DOI":"10.1016\/S0168-8278(17)31853-6","volume":"66","author":"S Joly","year":"2017","unstructured":"Joly S, Porcherot M, Radreau P, Vonderscher J, Andr\u00e9 P, Meldrum E et al (2017) The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells. J Hepatol 66(1):S690","journal-title":"J Hepatol"},{"issue":"4","key":"232_CR62","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1074\/jbc.M109326200","volume":"277","author":"HR Kast","year":"2002","unstructured":"Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM et al (2002) Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277(4):2908\u20132915","journal-title":"J Biol Chem"},{"issue":"6","key":"232_CR63","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jcmgh.2016.08.004","volume":"2","author":"SJ Keely","year":"2016","unstructured":"Keely SJ, Walters JRF (2016) The farnesoid X receptor: good for BAD. Cell Mol Gastroenterol Hepatol 2(6):725\u2013732","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"12","key":"232_CR64","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1194\/jlr.M700330-JLR200","volume":"48","author":"I Kim","year":"2007","unstructured":"Kim I, Ahn S-H, Inagaki T, Choi M, Ito S, Guo GL et al (2007) Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res 48(12):2664\u20132672","journal-title":"J Lipid Res"},{"issue":"15","key":"232_CR65","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1016\/j.bmcl.2016.05.070","volume":"26","author":"O Kinzel","year":"2016","unstructured":"Kinzel O, Steeneck C, Schl\u00fcter T, Schulz A, Gege C, Hahn U et al (2016) Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: understanding and improving key determinants of pharmacological properties. Bioorg Med Chem Lett 26(15):3746\u20133753","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"232_CR66","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jhep.2017.10.015","volume":"68","author":"MA Konerman","year":"2018","unstructured":"Konerman MA, Jones JC, Harrison SA (2018) Pharmacotherapy for NASH: current and emerging. J Hepatol 68(2):362\u2013375","journal-title":"J Hepatol"},{"issue":"3","key":"232_CR67","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/hep.25740","volume":"56","author":"B Kong","year":"2012","unstructured":"Kong B, Wang L, Chiang JYL, Zhang Y, Klaassen CD, Guo GL (2012) Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 56(3):1034\u20131043","journal-title":"Hepatology"},{"issue":"5","key":"232_CR68","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/hep.29569","volume":"67","author":"KV Kowdley","year":"2018","unstructured":"Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C et al (2018) A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology 67(5):1890\u20131902","journal-title":"Hepatology"},{"issue":"3","key":"232_CR69","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1053\/j.gastro.2010.05.009","volume":"139","author":"AE Kremer","year":"2010","unstructured":"Kremer AE, Martens JJWW, Kulik W, Ru\u00ebff F, Kuiper EMM, van Buuren HR et al (2010) Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 139(3):1008\u20131018.e1","journal-title":"Gastroenterology"},{"issue":"19\u201320","key":"232_CR70","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.drudis.2007.07.025","volume":"12","author":"C Kremoser","year":"2007","unstructured":"Kremoser C, Albers M, Burris TP, Deuschle U, Koegl M (2007) Panning for SNuRMs: using cofactor profiling for the rational discovery of selective nuclear receptor modulators. Drug Discov Today 12(19\u201320):860\u2013869","journal-title":"Drug Discov Today"},{"key":"232_CR71","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/S0168-8278(11)60101-3","volume":"54","author":"C Kremoser","year":"2011","unstructured":"Kremoser C, Hambruch E, Deuschle U, Kinzel O, Burnet M, Yoneyama H (2011) Novel FXR agonists with potent lipid lowering, insulin sensitising, anti-inflammatory and anti-fibrotisation effects in mouse models of metabolic syndrome and NASH. J Hepatol 54:S44","journal-title":"J Hepatol"},{"issue":"4","key":"232_CR72","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1074\/jbc.M209525200","volume":"278","author":"G Lambert","year":"2003","unstructured":"Lambert G, Amar MJA, Guo G, Brewer HB, Gonzalez FJ, Sinal CJ (2003) The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 278(4):2563\u20132570","journal-title":"J Biol Chem"},{"issue":"1","key":"232_CR73","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/cells8010031","volume":"8","author":"Liwei Lang","year":"2019","unstructured":"Lang L, Teng Y (2019) Fibroblast growth factor receptor 4 targeting in cancer: new insights into mechanisms and therapeutic strategies. Cells 8(1):31","journal-title":"Cells"},{"issue":"2","key":"232_CR74","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S1590-8658(18)30266-4","volume":"50","author":"NF Larusso","year":"2018","unstructured":"Larusso NF, Bowlus CL, Levy C, Vuppalanchi R, Floreani A, Andreone P et al (2018) The AESOP trial: a randomized, double-blind, placebo-controlled, phase 2 study of obeticholic acid in patients with primary sclerosing cholangitis. Dig Liver Dis 50(2):e67","journal-title":"Dig Liver Dis"},{"issue":"6","key":"232_CR75","doi-asserted-by":"publisher","first-page":"S-1166","DOI":"10.1016\/S0016-5085(18)33863-0","volume":"154","author":"E Lawitz","year":"2018","unstructured":"Lawitz E, Herring R, Younes ZH, Gane E, Ruane PJ, Aguilar R et al (2018) Proof of concept study of an apoptosis-signal regulating kinase (ASK-1) inhibitor (selonsertib) in combination with an acetyl-Coa carboxylase inhibitor (GS-0976) or a farnesoid X receptor (FXR) agonist (GS-9674) in NASH. Gastroenterology 154(6):S-1166\u2013S-1167","journal-title":"Gastroenterology"},{"issue":"10","key":"232_CR76","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1002\/ijc.26293","volume":"130","author":"S Lax","year":"2012","unstructured":"Lax S, Schauer G, Prein K, Kapitan M, Silbert D, Berghold A et al (2012) Expression of the nuclear bile acid receptor\/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis. Int J Cancer 130(10):2232\u20132239","journal-title":"Int J Cancer"},{"issue":"10","key":"232_CR77","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.tibs.2006.08.002","volume":"31","author":"FY Lee","year":"2006","unstructured":"Lee FY, Lee H, Hubbert ML, Edwards PA, Zhang Y (2006) FXR, a multipurpose nuclear receptor. Trends Biochem Sci 31(10):572\u2013580","journal-title":"Trends Biochem Sci"},{"issue":"5","key":"232_CR78","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1053\/j.gastro.2012.01.007","volume":"142","author":"CG Lee","year":"2012","unstructured":"Lee CG, Kim YW, Kim EH, Meng Z, Huang W, Hwang SJ et al (2012) Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1. Gastroenterology 142(5):1206\u20131217.e7","journal-title":"Gastroenterology"},{"issue":"1","key":"232_CR79","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00010.2008","volume":"89","author":"P Lefebvre","year":"2009","unstructured":"Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B (2009) Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 89(1):147\u2013191","journal-title":"Physiol Rev"},{"issue":"11","key":"232_CR80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013955","volume":"5","author":"J Li","year":"2010","unstructured":"Li J, Kuruba R, Wilson A, Gao X, Zhang Y, Li S (2010) Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand. PLoS One 5(11):e13955","journal-title":"PLoS One"},{"issue":"1","key":"232_CR81","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1124\/mol.110.068247","volume":"80","author":"J Li","year":"2011","unstructured":"Li J, Zhang Y, Kuruba R, Gao X, Gandhi CR, Xie W et al (2011) Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells. Mol Pharmacol 80(1):191\u2013200","journal-title":"Mol Pharmacol"},{"issue":"6","key":"232_CR82","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1053\/j.gastro.2014.08.042","volume":"147","author":"T Lieu","year":"2014","unstructured":"Lieu T, Jayaweera G, Zhao P, Poole DP, Jensen D, Grace M et al (2014) The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice. Gastroenterology 147(6):1417\u20131428","journal-title":"Gastroenterology"},{"issue":"2","key":"232_CR83","doi-asserted-by":"publisher","first-page":"S169","DOI":"10.1016\/S0168-8278(16)01682-2","volume":"64","author":"JT Liles","year":"2016","unstructured":"Liles JT, Karnik S, Hambruch E, Kremoser C, Birkel M, Watkins WJ et al (2016) Fxr agonism by Gs-9674 decreases steatosis and fibrosis in a murine model of nash. J Hepatol 64(2):S169","journal-title":"J Hepatol"},{"issue":"11","key":"232_CR84","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1172\/JCI18945","volume":"112","author":"Y Liu","year":"2003","unstructured":"Liu Y, Binz J, Numerick MJ, Dennis S, Luo G, Desai B et al (2003) Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 112(11):1678\u20131687","journal-title":"J Clin Invest"},{"issue":"1","key":"232_CR85","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbrc.2014.05.072","volume":"450","author":"X Liu","year":"2014","unstructured":"Liu X, Xue R, Ji L, Zhang X, Wu J, Gu J et al (2014) Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction. Biochem Biophys Res Commun 450(1):117\u2013123","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"232_CR86","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/hep.29815","volume":"68","author":"X Liu","year":"2018","unstructured":"Liu X, Guo GL, Kong B, Hilburn DB, Hubchak SC, Park S et al (2018) Farnesoid X receptor signaling activates the hepatic X-box binding protein 1 pathway in vitro and in mice. Hepatology 68(1):304\u2013316","journal-title":"Hepatology"},{"issue":"2","key":"232_CR87","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","volume":"68","author":"A Lonardo","year":"2018","unstructured":"Lonardo A, Nascimbeni F, Mantovani A, Targher G (2018) Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol 68(2):335\u2013352","journal-title":"J Hepatol"},{"issue":"11","key":"232_CR88","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","volume":"10","author":"R Loomba","year":"2013","unstructured":"Loomba R, Sanyal AJ (2013) The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10(11):686\u2013690","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"232_CR89","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S1097-2765(00)00050-2","volume":"6","author":"TT Lu","year":"2000","unstructured":"Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J et al (2000) Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 6(3):507\u2013515","journal-title":"Mol Cell"},{"issue":"4","key":"232_CR90","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1021\/jm901650u","volume":"53","author":"JT Lundquist","year":"2010","unstructured":"Lundquist JT, Harnish DC, Kim CY, Mehlmann JF, Unwalla RJ, Phipps KM et al (2010) Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates. J Med Chem 53(4):1774\u20131787","journal-title":"J Med Chem"},{"issue":"4","key":"232_CR91","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1172\/JCI25604","volume":"116","author":"K Ma","year":"2006","unstructured":"Ma K, Saha PK, Chan L, Moore DD (2006) Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 116(4):1102\u20131109","journal-title":"J Clin Invest"},{"issue":"5418","key":"232_CR92","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","volume":"284","author":"M Makishima","year":"1999","unstructured":"Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A et al (1999) Identification of a nuclear receptor for bile acids. Science 284(5418):1362\u20131365","journal-title":"Science"},{"issue":"16","key":"232_CR93","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1021\/jm0002127","volume":"43","author":"PR Maloney","year":"2000","unstructured":"Maloney PR, Parks DJ, Haffner CD, Fivush AM, Chandra G, Plunket KD et al (2000) Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 43(16):2971\u20132974","journal-title":"J Med Chem"},{"issue":"2","key":"232_CR94","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1124\/jpet.108.145409","volume":"328","author":"RRM Maran","year":"2009","unstructured":"Maran RRM, Thomas A, Roth M, Sheng Z, Esterly N, Pinson D et al (2009) Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther 328(2):469\u2013477","journal-title":"J Pharmacol Exp Ther"},{"key":"232_CR95","doi-asserted-by":"publisher","first-page":"S377","DOI":"10.1016\/S0168-8278(12)60976-3","volume":"56","author":"H-U Marschall","year":"2012","unstructured":"Marschall H-U, Luketic V, Lovgren-Sandblom A, Benthin L, Kowdley K, Hirschfield G et al (2012) 964 the farnesoid X receptor (FXR) agonist obeticholic acid (OCA) increases plasma FGF-19 concentrations and decreases bile acid synthesis in primary biliary cirrhosis (PBC). J Hepatol 56:S377","journal-title":"J Hepatol"},{"issue":"9","key":"232_CR96","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s00018-014-1805-y","volume":"72","author":"C Mazuy","year":"2015","unstructured":"Mazuy C, Helleboid A, Staels B, Lefebvre P (2015) Nuclear bile acid signaling through the farnesoid X receptor. Cell Mol Life Sci 72(9):1631\u20131650","journal-title":"Cell Mol Life Sci"},{"key":"232_CR97","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1471-2407-12-56","volume":"12","author":"S Miura","year":"2012","unstructured":"Miura S, Mitsuhashi N, Shimizu H, Kimura F, Yoshidome H, Otsuka M et al (2012) Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer 12:56","journal-title":"BMC Cancer"},{"issue":"23","key":"232_CR98","doi-asserted-by":"publisher","first-page":"9589","DOI":"10.1158\/0008-5472.CAN-08-1791","volume":"68","author":"S Modica","year":"2008","unstructured":"Modica S, Murzilli S, Salvatore L, Schmidt DR, Moschetta A (2008) Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res 68(23):9589\u20139594","journal-title":"Cancer Res"},{"issue":"2","key":"232_CR99","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1053\/j.gastro.2011.10.028","volume":"142","author":"S Modica","year":"2012","unstructured":"Modica S, Petruzzelli M, Bellafante E, Murzilli S, Salvatore L, Celli N et al (2012) Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 142(2):355\u2013365.e1\u20134","journal-title":"Gastroenterology"},{"issue":"3","key":"232_CR100","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","volume":"145","author":"S Mudaliar","year":"2013","unstructured":"Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall H-U, Kipnes M et al (2013) Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145(3):574\u2013582.e1","journal-title":"Gastroenterology"},{"issue":"4","key":"232_CR101","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/path.2657","volume":"220","author":"T Murphy","year":"2010","unstructured":"Murphy T, Darby S, Mathers ME, Gnanapragasam VJ (2010) Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. J Pathol 220(4):452\u2013460","journal-title":"J Pathol"},{"issue":"Suppl 1","key":"232_CR102","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/jcag\/gwy008.199","volume":"1","author":"RP Myers","year":"2018","unstructured":"Myers RP, Djedjos C, Kirby B, Bilin A, Khan M, Gosink J et al (2018) Pharmacodynamic effects of the oral, non-steroidal farnesoid X receptor agonist GS-9674 in healthy volunteers. J Can Assoc Gastroenterol 1(Suppl 1):346","journal-title":"J Can Assoc Gastroenterol"},{"issue":"9972","key":"232_CR103","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF et al (2015) Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385(9972):956\u2013965","journal-title":"Lancet"},{"issue":"7","key":"232_CR104","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P et al (2016) A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 375(7):631\u2013643","journal-title":"N Engl J Med"},{"issue":"6","key":"232_CR105","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/S0002-9440(10)61177-7","volume":"160","author":"K Nicholes","year":"2002","unstructured":"Nicholes K, Guillet S, Tomlinson E, Hillan K, Wright B, Frantz GD et al (2002) A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 160(6):2295\u20132307","journal-title":"Am J Pathol"},{"issue":"1","key":"232_CR106","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000324131","volume":"29","author":"RPJ Oude Elferink","year":"2011","unstructured":"Oude Elferink RPJ, Kremer AE, Martens JJWW, Beuers UH (2011) The molecular mechanism of cholestatic pruritus. Dig Dis 29(1):66\u201371","journal-title":"Dig Dis"},{"issue":"5418","key":"232_CR107","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","volume":"284","author":"DJ Parks","year":"1999","unstructured":"Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA et al (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284(5418):1365\u20131368","journal-title":"Science"},{"key":"232_CR108","unstructured":"Patel K, Harrison S, Trotter J, Herring R, Rojter S, Rinella M et al (2018) The nonsteroidal FXR agonist GS-9674 leads to significant reductions in hepatic steatosis, serum bile acids, and liver biochemistry in a phase 2, randomized, placebo-controlled trial of patients with NASH. Hepatology. http:\/\/www.natap.org\/2018\/AASLD\/AASLD_45.htm"},{"issue":"4","key":"232_CR109","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/hep.29857","volume":"68","author":"P Pathak","year":"2018","unstructured":"Pathak P, Xie C, Nichols RG, Ferrell JM, Boehme S, Krausz KW et al (2018) Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. Hepatology 68(4):1574\u20131588","journal-title":"Hepatology"},{"issue":"17","key":"232_CR110","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1021\/jm025529g","volume":"45","author":"R Pellicciari","year":"2002","unstructured":"Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR et al (2002) 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 45(17):3569\u20133572","journal-title":"J Med Chem"},{"issue":"6","key":"232_CR111","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMra020831","volume":"347","author":"DK Podolsky","year":"2002","unstructured":"Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347(6):417\u2013429","journal-title":"N Engl J Med"},{"key":"232_CR112","unstructured":"Press Release (2014). http:\/\/ir.interceptpharma.com\/news-releases\/news-release-details\/intercept-provides-2013-year-end-update-and-2014-anticipated"},{"issue":"2","key":"232_CR113","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/hep.29359","volume":"67","author":"Puneet Puri","year":"2017","unstructured":"Puri P, Daita K, Joyce A, Mirshahi F, Santhekadur PK, Cazanave S et al (2018) The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology 67(2):534\u2013548.","journal-title":"Hepatology"},{"issue":"9","key":"232_CR114","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1096\/fj.201500134","volume":"30","author":"P Radreau","year":"2016","unstructured":"Radreau P, Porcherot M, Rami\u00e8re C, Mouzannar K, Lotteau V, Andr\u00e9 P (2016) Reciprocal regulation of farnesoid X receptor \u03b1 activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes. FASEB J 30(9):3146\u20133154","journal-title":"FASEB J"},{"issue":"4","key":"232_CR115","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.bmcl.2010.12.123","volume":"21","author":"HGF Richter","year":"2011","unstructured":"Richter HGF, Benson GM, Bleicher KH, Blum D, Chaput E, Clemann N et al (2011a) Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties. Bioorg Med Chem Lett 21(4):1134\u20131140","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"232_CR116","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bmcl.2010.11.039","volume":"21","author":"HGF Richter","year":"2011","unstructured":"Richter HGF, Benson GM, Blum D, Chaput E, Feng S, Gardes C et al (2011b) Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes. Bioorg Med Chem Lett 21(1):191\u2013194","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"232_CR117","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","volume":"133","author":"C Ripoll","year":"2007","unstructured":"Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R et al (2007) Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 133(2):481\u2013488","journal-title":"Gastroenterology"},{"issue":"3","key":"232_CR118","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2174\/1568008054863781","volume":"5","author":"G Rizzo","year":"2005","unstructured":"Rizzo G, Renga B, Mencarelli A, Pellicciari R, Fiorucci S (2005) Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr Drug Targets Immune Endocr Metabol Disord 5(3):289\u2013303","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"232_CR119","unstructured":"Sanyal AJ, Lopez P, Lawitz E, Kim W, Huang J, Andreone P et al (2018) Tropifexor (TXR), an FXR agonist for the treatment of NASH \u2013 interim results from first two parts of phase 2b study FLIGHT-FXR. http:\/\/www.natap.org\/2018\/AASLD\/AASLD_168.htm"},{"issue":"1","key":"232_CR120","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrgastro.2013.151","volume":"11","author":"FG Schaap","year":"2014","unstructured":"Schaap FG, Trauner M, Jansen PLM (2014) Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 11(1):55\u201367","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"232_CR121","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/liv.12456","volume":"35","author":"J Schmitt","year":"2015","unstructured":"Schmitt J, Kong B, Stieger B, Tschopp O, Schultze SM, Rau M et al (2015) Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal. Liver Int 35(4):1133\u20131144","journal-title":"Liver Int"},{"issue":"4","key":"232_CR122","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","volume":"66","author":"P Schwabl","year":"2017","unstructured":"Schwabl P, Hambruch E, Seeland BA, Hayden H, Wagner M, Garnys L et al (2017) The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. J Hepatol 66(4):724\u2013733","journal-title":"J Hepatol"},{"issue":"6","key":"232_CR123","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","volume":"102","author":"CJ Sinal","year":"2000","unstructured":"Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ (2000) Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis. Cell 102(6):731\u2013744","journal-title":"Cell"},{"issue":"14","key":"232_CR124","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1073\/pnas.0710981105","volume":"105","author":"SM Soisson","year":"2008","unstructured":"Soisson SM, Parthasarathy G, Adams AD, Sahoo S, Sitlani A, Sparrow C et al (2008) Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation. Proc Natl Acad Sci U S A 105(14):5337\u20135342","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"232_CR125","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1210\/en.2004-0965","volume":"146","author":"KR Stayrook","year":"2005","unstructured":"Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME et al (2005) Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 146(3):984\u2013991","journal-title":"Endocrinology"},{"key":"232_CR126","unstructured":"Stringer (2019) Safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis (TANDEM). Full text view - ClinicalTrials.gov [Internet]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03517540"},{"issue":"20","key":"232_CR127","doi-asserted-by":"publisher","first-page":"10120","DOI":"10.1158\/0008-5472.CAN-06-2399","volume":"66","author":"KE Swales","year":"2006","unstructured":"Swales KE, Korbonits M, Carpenter R, Walsh DT, Warner TD, Bishop-Bailey D (2006) The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res 66(20):10120\u201310126","journal-title":"Cancer Res"},{"issue":"11","key":"232_CR128","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.tem.2011.07.002","volume":"22","author":"JS Teodoro","year":"2011","unstructured":"Teodoro JS, Rolo AP, Palmeira CM (2011) Hepatic FXR: key regulator of whole-body energy metabolism. Trends Endocrinol Metabol 22(11):458\u2013466","journal-title":"Trends Endocrinol Metabol"},{"issue":"8","key":"232_CR129","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.cgh.2012.03.011","volume":"10","author":"DM Torres","year":"2012","unstructured":"Torres DM, Williams CD, Harrison SA (2012) Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 10(8):837\u2013858","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"232_CR130","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/hep.30509","volume":"70","author":"Michael Trauner","year":"2019","unstructured":"Trauner M, Gulamhusein A, Hameed B, Caldwell S, Shiffman ML, Landis C et al (2019) The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC. Hepatology. https:\/\/doi.org\/10.1002\/hep.30509","journal-title":"Hepatology"},{"issue":"7","key":"232_CR131","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida T, Friedman SL (2017) Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 14(7):397\u2013411","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"24","key":"232_CR132","doi-asserted-by":"publisher","first-page":"9960","DOI":"10.1021\/acs.jmedchem.7b00907","volume":"60","author":"DC Tully","year":"2017","unstructured":"Tully DC, Rucker PV, Chianelli D, Williams J, Vidal A, Alper PB et al (2017) Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH). J Med Chem 60(24):9960\u20139973","journal-title":"J Med Chem"},{"issue":"10","key":"232_CR133","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1002\/ijc.29287","volume":"136","author":"I Uriarte","year":"2015","unstructured":"Uriarte I, Latasa MU, Carotti S, Fernandez-Barrena MG, Garcia-Irigoyen O, Elizalde M et al (2015) Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development. Int J Cancer 136(10):2469\u20132475","journal-title":"Int J Cancer"},{"issue":"6","key":"232_CR134","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/hep.26939","volume":"59","author":"L Verbeke","year":"2014","unstructured":"Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S et al (2014) Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 59(6):2286\u20132298","journal-title":"Hepatology"},{"issue":"4","key":"232_CR135","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jhep.2017.01.013","volume":"66","author":"L Verbeke","year":"2017","unstructured":"Verbeke L, Nevens F, Laleman W (2017) Steroidal or non-steroidal FXR agonists \u2013 is that the question? J Hepatol 66(4):680\u2013681","journal-title":"J Hepatol"},{"issue":"1","key":"232_CR136","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/apt.12999","volume":"41","author":"JRF Walters","year":"2015","unstructured":"Walters JRF, Johnston IM, Nolan JD, Vassie C, Pruzanski ME, Shapiro DA (2015) The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther 41(1):54\u201364","journal-title":"Aliment Pharmacol Ther"},{"issue":"18 Pt 1","key":"232_CR137","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.1158\/1078-0432.CCR-04-0408","volume":"10","author":"J Wang","year":"2004","unstructured":"Wang J, Stockton DW, Ittmann M (2004) The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 10(18 Pt 1):6169\u20136178","journal-title":"Clin Cancer Res"},{"issue":"11","key":"232_CR138","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/cr.2008.289","volume":"18","author":"Y-D Wang","year":"2008","unstructured":"Wang Y-D, Chen W-D, Moore DD, Huang W (2008a) FXR: a metabolic regulator and cell protector. Cell Res 18(11):1087\u20131095","journal-title":"Cell Res"},{"issue":"5","key":"232_CR139","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/hep.22519","volume":"48","author":"Y-D Wang","year":"2008","unstructured":"Wang Y-D, Chen W-D, Wang M, Yu D, Forman BM, Huang W (2008b) Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 48(5):1632\u20131643","journal-title":"Hepatology"},{"issue":"47","key":"232_CR140","doi-asserted-by":"publisher","first-page":"18180","DOI":"10.1074\/jbc.RA118.004652","volume":"293","author":"N Wang","year":"2018","unstructured":"Wang N, Zou Q, Xu J, Zhang J, Liu J (2018) Ligand binding and heterodimerization with retinoid X receptor \u03b1 (RXR\u03b1) induce farnesoid X receptor (FXR) conformational changes affecting coactivator binding. J Biol Chem 293(47):18180\u201318191","journal-title":"J Biol Chem"},{"issue":"10","key":"232_CR141","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1172\/JCI21025","volume":"113","author":"M Watanabe","year":"2004","unstructured":"Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA et al (2004) Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 113(10):1408\u20131418","journal-title":"J Clin Invest"},{"issue":"1","key":"232_CR142","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbrc.2014.02.050","volume":"446","author":"Y-F Xu","year":"2014","unstructured":"Xu Y-F, Yang X-Q, Lu X-F, Guo S, Liu Y, Iqbal M et al (2014) Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma. Biochem Biophys Res Commun 446(1):54\u201360","journal-title":"Biochem Biophys Res Commun"},{"key":"232_CR143","doi-asserted-by":"publisher","first-page":"e00049","DOI":"10.7554\/eLife.00049","volume":"1","author":"H Yan","year":"2012","unstructured":"Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z et al (2012) Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. elife 1:e00049","journal-title":"elife"},{"issue":"3","key":"232_CR144","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1158\/0008-5472.CAN-06-1078","volume":"67","author":"F Yang","year":"2007","unstructured":"Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W (2007) Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res 67(3):863\u2013867","journal-title":"Cancer Res"},{"issue":"11","key":"232_CR145","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","volume":"2","author":"H Yki-J\u00e4rvinen","year":"2014","unstructured":"Yki-J\u00e4rvinen H (2014) Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2(11):901\u2013910","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"232_CR146","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.febslet.2007.11.015","volume":"582","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, Edwards PA (2008) FXR signaling in metabolic disease. FEBS Lett 582(1):10\u201318","journal-title":"FEBS Lett"},{"issue":"4","key":"232_CR147","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1073\/pnas.0506982103","volume":"103","author":"Y Zhang","year":"2006","unstructured":"Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ et al (2006) Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 103(4):1006\u20131011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"232_CR148","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","volume":"51","author":"S Zhang","year":"2009","unstructured":"Zhang S, Wang J, Liu Q, Harnish DC (2009) Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol 51(2):380\u2013388","journal-title":"J Hepatol"},{"issue":"12","key":"232_CR149","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-14-0208","volume":"74","author":"M Zhou","year":"2014","unstructured":"Zhou M, Wang X, Phung V, Lindhout DA, Mondal K, Hsu J-Y et al (2014) Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. Cancer Res 74(12):3306\u20133316","journal-title":"Cancer Res"}],"container-title":["Handbook of Experimental Pharmacology","Bile Acids and Their Receptors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2019_232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T01:10:00Z","timestamp":1649812200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2019_232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030220044","9783030220051"],"references-count":150,"URL":"https:\/\/doi.org\/10.1007\/164_2019_232","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"14 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}